エピソード

  • Prior Auth Gets Adrenalized and Dangerous Trials in China

    Prior Auth Gets Adrenalized and Dangerous Trials in China
    2026/08/28
    Friday, August 28, 2026 In today's episode, Alok Patel (@AlokPatelMD) & Adam Rose (@Adjoro) cover Epic bringing prior authorization checks directly into the EHR. New federal rules will require Medicare Advantage Medicaid and ACA marketplace insurers to support electronic prior authorization APIs by January 1. Epic's Coverage Requirements Discovery shows coverage requirements and documentation needs inside the chart without payer portals or phone calls. They also break down undisclosed deaths in Chinese gene editing trials involving high dose AAV9 vectors and what the delays reveal about safety oversight. Plus: they discuss the Oura sleep tracking lawsuit and new real world psilocybin data from Oregon and more. Coverage Timeline: (00:00) Intro (01:03) Electronic Prior Auth (03:41) Gene Editing Deaths (06:41) Measles Outbreak (07:23) MyChart Phishing Scam (08:05) Mediterranean Diet (08:47) Legal Psilocybin Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    続きを読む 一部表示
    13 分
  • Milestone Prescription Price Drops and the CTE Diagnostic Puzzle

    Milestone Prescription Price Drops and the CTE Diagnostic Puzzle
    2026/08/21
    Friday, August 21, 2026 In today's episode, Dr. Will Flanary (@drglaucomflecken) & Eva Johnson cover a historic drop in prescription drug prices. Prices fell 3.1% over the past year, the steepest annual decline since 1963, and the anchors unpack what is actually driving it from generics to GLP-1 competition to the Inflation Reduction Act. They also break down why the national index does not always match what patients pay at the pharmacy counter. Plus: a split between two studies on whether CTE can be diagnosed in living patients, and more. Coverage Timeline: (00:00) Intro (01:04) Drug Prices Drop (04:25) Diagnosing CTE in Living Patients (08:18) Waist Size vs BMI (09:26) C. Diff Treatment Updates Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit https://www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    続きを読む 一部表示
    13 分
  • FDA Approves mRNA Flu Shot and AI Learns to Build Viruses

    FDA Approves mRNA Flu Shot and AI Learns to Build Viruses
    2026/08/14
    Friday, August 14, 2026 In today's episode, Adam Rose (@adjoro) & Dr. Alok Patel (@alokpatelmd) cover the FDA's landmark approval of Moderna's first mRNA flu vaccine for adults. They break down the phase-three trial showing the mRNA shot produced fewer confirmed influenza cases than standard vaccines, and what a complicated insurance landscape means for access this flu season. Plus: researchers at the Arc Institute fed millions of viral DNA sequences to a language model. It wrote new genomes that had never existed in nature, and sixteen of them came to life in the lab. Then, they look at a new narcolepsy drug targeting the underlying orexin deficiency, a Salmonella outbreak linked to jalapeños spreading through 27 states, and over 2,400 measles cases putting U.S. elimination status in jeopardy. Coverage Timeline: (0:00) Intro (1:01) First mRNA Flu Vaccine Approved (4:52) AI Designs Functional Viruses (8:54) Salmonella Jalapeño Outbreak (9:44) Measles Resurgence (10:04) Women's Pro Baseball Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    続きを読む 一部表示
    13 分
  • Our Blood Donation Crisis & An Organ Transplant First

    Our Blood Donation Crisis & An Organ Transplant First
    2026/08/07
    August 7, 2026 In today's episode, Dr. Will Flanary (@DrGlaucomflecken) & Eva Johnson cover the American Red Cross declaring its second-ever national blood crisis, with Type O blood critically low and hospitals postponing transfusions. They break down what's driving the shortage and debate whether blood donors deserve HOV-lane perks. Then: a 36-year-old Iowa woman with cystic fibrosis becomes the first known U.S. patient to receive a quadruple organ transplant involving re-transplanted lungs, in addition to a liver and kidney, at Northwestern Medicine. Plus: Florida advises caution on psychiatric medication for children, a promising non-opioid pain drug (LTG-001) reduces opioid use after surgery, and Will reveals whether he actually knows his blood type. Coverage Timeline: (0:00) Intro & Trivia Question (1:00) Red Cross Blood Crisis (3:54) Should We Pay Blood Donors? (4:44) Historic 4-Organ Transplant (8:32) Florida Psych Meds Debate (10:04) Non-Opioid Pain Relief Trial Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    続きを読む 一部表示
    14 分
  • The ChatGPT Medical Lawsuit & Why Statin Rules Just Changed

    The ChatGPT Medical Lawsuit & Why Statin Rules Just Changed
    2026/07/31
    Friday, July 31, 2026 In today's episode, Dr. Alok Patel (@alokpatelmd) & Adam Rose (@adjoro) cover a Florida man's lawsuit against OpenAI after ChatGPT repeatedly dismissed his pulmonary embolism symptoms as "not something dangerous." The case raises urgent questions about AI medical liability just as a new JAMA analysis reveals updated cholesterol guidelines now make 87.5 million US adults eligible for statins (more than 56% of the 30-to-79 population). Plus: they also discuss the FDA's first dual-ingredient OTC pain reliever, Lego MRI models cutting pediatric sedation rates by nearly half, and Europe's approval of a retinal implant that helped 84% of participants read again. Plus: oral GLP-1 competition heats up and a new smell-impairment and depression link. (00:00) Intro & Trivia Question (01:05) AI Medical Advice Lawsuit (OpenAI/ChatGPT) (04:34) New Cholesterol Guidelines & Statin Eligibility (07:05) Off The Clock GLP-1s, Lego MRI, OTC Pain Combo (11:03) Trivia Answer Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    続きを読む 一部表示
    14 分
  • Kalshi Prediction Market and CMS's 2027 Fee Schedule Overhaul

    Kalshi Prediction Market and CMS's 2027 Fee Schedule Overhaul
    2026/07/24
    Friday, July 24, 2026 In today's episode, Dr. Alok Patel (@alokpatelmd) & Eva Johnson cover CMS's sweeping 2027 physician fee schedule proposal, which would accelerate Medicare's shift from fee-for-service toward value-based, preventive care. They also unpack Kalshi's launch of clinical trial prediction markets; betting on FDA approvals is now a real thing, and the ethical questions are piling up. Coffee gets a heart health endorsement from the AHA, and an outbreak of Legionnaires' disease hits Manhattan's Upper East Side. Last, but far from least, we discuss the FDA's transparency whiplash on rejection letters, the first RCT of a ketogenic diet for severe mental illness, and more. Coverage Timeline: (00:00) Intro & Trivia Question (01:17) Medicare Physician Payment Overhaul (04:30) Prediction Markets for Clinical Trials (07:12) Off the Clock: FDA, Coffee, Outbreak, Ketogenic Diet (09:57) Trivia Answer (11:07) Outro & Disclaimers Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    続きを読む 一部表示
    13 分
  • Aspirin vs. Blood Thinners, a 9-Year Endo Wait Ends & Cyclospora Hits Taco Bell

    Aspirin vs. Blood Thinners, a 9-Year Endo Wait Ends & Cyclospora Hits Taco Bell
    2026/07/17
    Friday, July 17, 2026 In today’s episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) and Adam Rose cover the EPCAT III trial, which found that aspirin alone was non-inferior to an initial course of rivaroxaban followed by aspirin for preventing major blood clots after elective hip or knee replacement in predominantly standard-risk patients. They examine NICE’s draft recommendation allowing two rapid endometriosis tests, EndoSure and Endotest, to enter limited NHS use while researchers gather additional real-world evidence. Plus: They discuss a recall involving more than 2.5 million bottles of prednisolone acetate eye drops, the first HAVANA Act compensation payments, the expanding Cyclospora response, and The Pitt leading the 2026 Emmy nominations with 25 nods. Coverage Timeline: (00:00) Intro (01:07) Aspirin vs. Rivaroxaban After Joint Replacement (03:19) NICE Endorses Rapid Endometriosis Tests (05:30) FDA Recall of Prednisolone Eye Drops (06:07) First Havana Syndrome Payments (06:41) Cyclospora Outbreak Reaches Taco Bell (07:10) The Pitt Leads Emmy Nominations Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today’s Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    続きを読む 一部表示
    11 分
  • Medicare's $50 GLP-1 Program, an Altered Drug Trial & Cyclospora's 18-State Spread

    Medicare's $50 GLP-1 Program, an Altered Drug Trial & Cyclospora's 18-State Spread
    2026/07/10
    Friday, July 10, 2026 In today's episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) & Eva Johnson cover the retraction of the Advocate trial after FDA reviewers found the avacopan (Tavneos) dataset was unblinded, re-adjudicated, and altered before being relocked, throwing its approval for ANCA-associated vasculitis into doubt. They break down Medicare's new GLP-1 Bridge program, which offers eligible Part D beneficiaries drugs like Wegovy and Zepbound at $50 a month through the end of 2027, and why that copay sits outside normal Part D accounting. They also track a Cyclospora outbreak now reported across 18 states and why routine washing does not reliably kill it. Plus: they also discuss Alibaba's $600 million fentanyl-precursor settlement, the WHO's first emergency-use Ebola (Bundibugyo) diagnostic, France's deadly heat wave, and more. Coverage Timeline: (00:00) Intro(01:04) Vasculitis Trial Retracted:(03:44) Medicare’s GLP‑1 Bridge(06:02) Parasite, Ebola, Heat Wave Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    続きを読む 一部表示
    12 分